Fullerton Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Fullerton Fund Management's REGN Position: Q2 2026 in Review
Fullerton Fund Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.9% in Q2 2026, buying an estimated $4.76K and bringing the position to 783 shares worth $488K. The position accounts for 0.03% of the portfolio, ranked #72.
Fullerton Fund Management first reported a position in REGN in Q3 2020 and has held it in 8 quarters since. The position peaked at $791K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Fullerton Fund Management held 783 shares of Regeneron Pharmaceuticals worth $488K as of Q2 2026.
- Fullerton Fund Management bought 7 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.76K.
- Regeneron Pharmaceuticals made up 0.03% of Fullerton Fund Management's portfolio in Q2 2026, its #72 holding.
- Fullerton Fund Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 8 quarters since.
- Fullerton Fund Management's Regeneron Pharmaceuticals position peaked at $791K in Q4 2025.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Fullerton Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.